GDTC
CytoMed Therapeutics Limited Ordinary SharesNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$11.90M
P/E Ratio
—
EPS
$-0.26
Beta
-0.35
52W High
$3.68
52W Low
$0.73
50-Day MA
$1.02
200-Day MA
$1.68
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About CytoMed Therapeutics Limited Ordinary Shares
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company is headquartered in Singapore.
Fundamentals
| Revenue (TTM) | $1.14M |
| Gross Profit (TTM) | $1.08M |
| EBITDA | $-3.57M |
| Operating Margin | -278.40% |
| Return on Equity | -50.30% |
| Return on Assets | -27.50% |
| Revenue/Share (TTM) | $0.10 |
| Book Value | $0.43 |
| Price-to-Book | 2.28 |
| Price-to-Sales (TTM) | 10.40 |
| EV/Revenue | 40.94 |
| EV/EBITDA | -4.45 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -25.20% |
| Shares Outstanding | $11.73M |
| Float | $3.77M |
| % Insiders | 66.46% |
| % Institutions | 0.49% |
Data last updated: 4/8/2026